4 Healthcare Stocks To Focus On Today

The global healthcare market is forecast to hit $53.65 billion by 2025, according to a report by Grand View Research. There are several factors accountable for driving the growth of the healthcare industry such as the reduction of healthcare spending among hospitals and providers, improved technology and the rising use of data-enriched products like mHealth, eHealth, Electronic Health Records and mobile apps.

healthcarestocks.jpg

Multi-Trillion Dollar Industry Providing Massive Opportunity In 2019 & Beyond 

The report detailed, “with the combination of artificial and human intelligence data analytics, which offer wide opportunities to further customize medical approaches, the demand for these tools is anticipated to increase over the forecast period”.

Healthcare companies seeking to develop innovative and effective solutions to advance the quality of care could catalyze opportunities for investors looking to healthcare stocks.

Premier Health Group (PHGRF) (PHGI.CN)a company focused on innovative healthcare approaches that combine human skill-based expertise with emerging technologies, announced that further to its previous news release, it has entered into a share purchase agreement to acquire two cash flow positive Metro Vancouver pharmacies. The pharmacies had combined annual revenue of approximately $6 million for the fiscal year ended August 31, 2018, and Premier Health expects to complete the acquisition during Q2 2019.

“We are very excited about this opportunity to acquire two well-run and profitable pharmacies.  As part of our patient centric model, fill and fulfillment is a major component of our telemedicine app.  We are also pleased to have the pharmacies’ key management team, with over 20 years’ of combined experience managing pharmacies, come on board to continue running operations. In light of our recent announcement of our medical cannabis decision tool for our JUNO EMR clients, our pharmacists will be able to help with patient education and support regarding medical cannabis” said Dr. Essam Hamza, CEO. “In addition, with one of the pharmacies occupying a space of over 6,000 square feet, we have the potential to open a new medical and/or cannabis clinic within the existing space.”

This news followed the announcement that the company has initiated integration of CB2 Insights’ (CBII.CN) medical cannabis Clinical Decision Support (CDS) tool to provide Premier Health’s over 4600 physicians using its Juno EMR platform access to the industry’s sole medical cannabis-specific CDS tool. Premier Health has also recently partnered with Bio Conscious Technologies (BCT) to bring their artificial intelligence (AI) technology to Premier Health’s user base for improved monitoring and management of chronic conditions, such as diabetes.

Avinger, Inc. (AVGR), a commercial stage medical device company, announced that it has received 510(k) clearance from the U.S. FDA for its Pantheris SV (Small Vessel) image-guided atherectomy system, a product line extension of its Lumivascular image-guided atherectomy platform.  The Pantheris SV device is designed for the diagnosis and treatment of Pulmonary Artery Disease (PAD) in small vessels, 2 to 4 millimeters in diameter, with its lower profile and longer length.

“We are excited to receive U.S. pre-marketing clearance for Pantheris SV, which we believe could expand our addressable market for atherectomy procedures by as much as 50%,” said Jeff Soinski, Avinger’s President and CEO. “With the clearance of this new device, we are well-positioned to build on the positive momentum we have seen in our Pantheris business since the introduction of the next-generation system in 2018. Following our anticipated limited launch of Pantheris SV, we plan on leveraging our growing commercial infrastructure and installed base of Lumivascular accounts to efficiently scale up the introduction of Pantheris SV and drive growth of our Pantheris product family in the second half of 2019.”

Back in October, the device received CE Marking and the first patients were treated with the device in Germany in November.  Avinger plans to have a limited launch of the device in several U.S. sites when commercial product is available.  According to the company, this new device is expected to increase the available market for the company up to 50%.

Precipio, Inc. (PRPO), a specialty diagnostics company, announced that it is negotiating a definitive agreement with a manufacturer to produce its patented IV-Cell media.  According to the company, the manufacturing partner comes with experience and large volume manufacturing capabilities.  Furthermore, it has the embedded quality-control processes, and the various ISO-related certifications required to mass-produce the media for global distribution.

“This is an exciting time for us, as we move towards the start of commercializing the technologies we’ve developed,” said Ilan Danieli, CEO. “The company and its shareholders deserve to reap the benefits of the innovative products developed, as we translate ideas in the laboratory into products – and revenue, for the company.”

This news followed the announcement of Methodist Hospital, of Memphis, TN, selecting Precipio’s HemeScreen assay for use in its molecular hematology testing laboratory. HemeScreen’s average turnaround time is 2- 4 days, compared to 2 weeks. According to the company, this deal may generate between $50-100K in revenue annually.

Hemispherx Biopharma, Inc.  (HEB), an immuno-pharma R&D and emerging commercial growth company, announced the first participant received initial dosing in its clinical trial sponsored by Roswell Park Comprehensive Cancer Center evaluating the company’s experimental drug Ampligen® (rintatolimod) in combination with Merck’s Keytruda® (pembrolizumab) for the treatment of metastatic triple-negative breast cancer.

“We are very excited to see the first patient treated as part of this important clinical trial evaluating Ampligen in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. We could not ask for better partners than the world-class team at Roswell Park Comprehensive Cancer Center, as we seek to evaluate the impact of the combined therapy on this high risk and very sick patient population,” said CEO Thomas K. Equels.

“Our extensive work with Ampligen has led many top oncologists to conclude, including in peer reviewed medical journal articles, that Ampligen has the potential to change the tumor microenvironment. Making tumors easier targets for checkpoint blockade therapies creates an exciting new approach with the potential to significantly improve clinical outcomes for patients in multiple solid tumor cancer types.”

biotechstocks.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. Midam owns zero shares of Premier Health Group Inc., which they purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Advertisements

3 Healthcare Stocks That May Keep Your Portfolio Healthy

As medical experts and scientists discover diseases, healthcare companies are ready to tackle these challenges by developing top-quality treatments.   Because of this, the healthcare sector manages to remain above the curve, which in turn leads to growth.  According Deliotte, global health expenditures are forecast to rise as healthcare spending is expected to increase 5.4% annually between 2017-2022, amounting to $10.059 trillion.

healthcarestocks.jpg

“The emergence of personalized medicine, increased use of exponential technologies, entry of disruptive and non-traditional competitors, the demand for expanded care delivery sites, and revamped payment and public funding models are all impacting the financial performance of the health care ecosystem. The health care market is looking to health technology for help.”

With chronic diseases running rampant, the demand for innovative healthcare solutions is rising rapidly.  As healthcare companies are working to develop fresh and innovative approaches, whether it be technology, devices or drugs, several healthcare stocks are beginning to see higher activity in the markets.

Premier Health Group (PHGRF) (PHGI.CN) , focuses on innovative healthcare approaches that combine human skill-based expertise with emerging technologies, announced it has initiated integration of CB2 Insights’ (CBII.CN) medical cannabis Clinical Decision Support (CDS) tool.  This agreement provides Premier Health’s over 4600 physicians using its Juno EMR platform access to the industry’s sole medical cannabis-specific CDS tool, which is designed to include medical cannabis into patient treatment plans and overcome barriers from a lack of access to education, qualification factors, risks and benefits of cannabinoid therapy while remaining on a patient-centered basis using clinically-validated data.

“We are dedicated to finding new ways to create value for our physician network,” said Dr. Essam Hamza, CEO. “We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner.”

This news followed the company’s announcement partnering Bio Conscious Technologies (BCT) to bring their artificial intelligence (AI) technology to Premier Health’s user base for improved monitoring and management of chronic conditions, such as diabetes.  The integration of BCT’s algorithm DiaBits into Premier Health’s patient-centric app can learn an individual’s physiology and with machine learning technology predict where their blood sugar will trend over time based on their past.

AVEO Oncology Inc (AVEO) announced financial results earlier this month for the full year ended December 31, 2018 and a business update. The company reported narrowing its Q4 net loss per share to $0.03, from $0.08 the year prior and saw revenue increase to $1.48 million from the previous year’s $82,000. AVEO stated that it believes that its $24.4 million in cash, cash equivalents, and marketable securities at the end of 2018 combined with the $7.5 million from sales under an agreement with SVB Leerink should allow it to fund planned operations into Q1 2020.

Furthermore, last month the company presented top-line results from the TIVO-3 trial, AVEO’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in 350 subjects with refractory advanced or metastatic renal cell carcinoma at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium.

“The results of TIVO-3, presented in February at the 2019 ASCO GU Symposium, underscore a unique activity and tolerability profile among VEGF TKIs in the treatment of kidney cancer,” said Michael Bailey, President CEO. “We continue to believe that there is a significant potential commercial opportunity for an active and well tolerated therapy within the third plus line of therapy, particularly one that demonstrated activity in a highly refractory patient population that has received prior PD-1 treatment. We are hopeful that the positive PFS outcomes from TIVO-3 translate into an improved overall survival hazard ratio and look forward to reporting a more mature interim OS outcome in the fourth quarter of 2019.”

Amarin Corporation plc (AMRN) announced that the American Diabetes Association® (ADA) issued important updates to the Standards of Medical Care in Diabetes for 2019 which include updates related to the results of the REDUCE-IT™ cardiovascular outcomes study. The REDUCE-IT related updates were informed by newly published research covering REDUCE-IT results.

The Standards of Care update references the drug, icosapent ethyl, which is studied in Amarin’s REDUCE-IT that evalutes Vascepa® (icosapent ethyl) capsules. Vascepa has been approved for use by the US FDA as an aide to diet to reduce triglyceride levels for severe hypertriglyceridemia. Amarin has begun transmission of data to the FDA to support the submission of a supplemental new drug application to expand Vascepa’s FDA label based on the landmark REDUCE-IT results.

“As we have commenced transmission of data to the FDA for the submission of our sNDA seeking an expansion of the Vascepa label based on the landmark REDUCE-IT results, we are pleased by ADA’s acknowledgement of the importance of the REDUCE-IT results in its 2019 update of the Standards of Care,” said Craig B. Granowitz, M.D., Ph.D., SVP, CMO. “The medical community will also hopefully take note of recent research reporting the prevalence of, and increased costs associated with, diabetes mellitus and high triglyceride levels despite statin therapy5.”

healthcarestocks1.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. Midam owns zero shares of Premier Health Group Inc., which they purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

4 Healthcare Stocks Gaining Momentum On Friday

Healthcare stocks are gaining momentum again this week, as sector trends in technology and new treatments are generating interest among investors. According to Modern Healthcare, “the healthcare industry has long fueled the country’s economy. Demand is expected to pick up as the population ages, people live longer, more gain insurance coverage and chronic conditions become more prevalent”.

biotechstocks.jpg

As healthcare companies work to develop new methods to improve the quality of care, whether it be technology, devices or drugs, many stocks within the sector are beginning to see higher activity in the markets.

Premier Health Group, Inc. (PHGRF) (PHGI) announced it is working with NexTech AR Solutions (NEXCF) to explore bringing augmented reality technology to its patient centric healthcare app to develop education tools for healthcare professionals and patients alike – some of which will be created and commercialized content for third parties.

“At Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient centric telemedicine app,” said Dr. Essam Hamza, CEO. “AR has the potential to revolutionize both the access to data and the delivery of healthcare. The technology will help doctors and patients alike – doctors will have access to the latest and most relevant information about their patients while patients can use AR for self-education and improving the quality of treatment they receive.”

Premier Health recently announced the launch of a technology enabled mental health initiative to focus on providing app enabled mental health counselling for patients as well as growing its development team at Cloud Practice to support the build out of its patient centric platform and mobile app – a beta version of which will be available by end of Q2 will initially be extended to the 290 clinics in Premier Health’s ecosystem.

Premier Health other recent announcements include expansion plans to formally enter the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers to develop a partnership. The company is also in the process of closing on two operating pharmacies in Metro Vancouver and entered into a partnership with a major online healthcare company in China, 360 Health enabling the Premier’s healthcare team to connect with patients virtually in China to provide second opinion services.

Trovagene, Inc. (TROV) today Noble Financial reiterated its coverage on the company to outperform and lowered the price target from $27 to $20. Trovagene announced company highlights and financial results for Q4 and full-year ended December 31, 2018 earlier this week.  The company reported quarterly losses of $(1.09) narrowing losses from $(4.61) a share the year prior, while quarterly sales of $78 thousand reflected a 57.84 percent decrease compared to last year’s sales of $185 thousand.

“We achieved a number of key milestones in 2018, including: Successful completion of the first three dose levels, without any dose-limiting toxicities, in the Phase 1b segment of our AML trial; granting of Orphan Drug Designation in Europe for the treatment of AML; presentation of preliminary clinical data from our AML trial at the American Society of Hematology (ASH) conference in December; opening of our mCRPC Phase 2 trial to full enrollment, following confirmation that the combination of onvansertib and Zytiga® is safe and well tolerated in the safety lead-in phase; submission of a new IND and protocol for our Phase 1b/2 trial in mCRC in December; strengthening of our patent portfolio around our drug candidate, onvansertib, with the issuance of two new patents; and entering into an exclusive license agreement with MIT to develop combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor (onvansertib) for the treatment of cancer.” said Dr. Thomas Adams, CEO and Chairman.

Trovagene announced that two abstracts, highlighting data from its lead clinical programs of onvansertib in AML and mCRPC have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, March 29 – April 3, 2019 in Atlanta, GA.

Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the European Patent Office issued European Patent No. 3246031 to the company on February 27, 2019 is expected to provide market exclusivity until April 2029.

The patent, “Method for Treating Neurodegenerative Dysfunction,” claims the use of TNX-601for treating neurocognitive dysfunction associated with corticosteroid treatment. Patents claiming the use of TNX-601, its structural analogs, and salts have previously been issued in the U.S., Canada and Europe.

“The grant of this European method of use patent is another step in expanding the patent portfolio for TNX-601,” commented Seth Lederman, M.D., President and CEO. “Tianeptine oxalate, or TNX-601, is an important product in our pipeline and is being developed not only for steroid-induced neurocognitive impairment, but also as a daytime treatment for posttraumatic stress disorder. We are conducting a non-IND human pharmacokinetic study of a proprietary tianeptine oxalate formulation and expect to have data in the second half of this year.”

Seelos Therapeutics, Inc. (SEEL) announced that it has acquired an exclusive license to intellectual property owned by The Regents of the University of California pertaining to a technology created by researchers at the University of California, Los Angeles (UCLA). The technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein).

Seelos intends to study this initial approach in Parkinson’s disease (PD) and will further evaluate the potential clinical approach in other central nervous system disorders. This new program will be dubbed SLS-007. Pre-clinical data provides supportive evidence to slow progression – an early sign of disease-modifying potential in PD. Under the terms of the agreement, Seelos has made an upfront payment of $100,000 and will issue future payment in the form of royalties, contingent upon commercialization.

“Despite current available treatments for PD, including levodopa and deep brain stimulation, long-term outcomes for patients remain poor,” said Tim Whitaker, MD, Head of R&D. “With no disease-modifying treatments, and long-term use of established dopaminergic therapies resulting in both adverse events and side effects, significant need remains to develop not only a better means of restoring striatal dopamine but a safe and effective treatment that slows progression of the disease in patients with PD. If we are successful in our planned pre-clinical and future clinical studies, SLS-007 may prove to be such a treatment.”

healthcarestocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.

3 Healthcare Stocks That May Grow Your Portfolio

The global medical technology industry’s market size is currently around USD $400 billion and is forecast to hit USD $495 billion over the next three years, according to a PwC report. The term “medical technology” covers a broad range of products, from devices to drugs as well as software. Technological advancements in the industry assist to save lives by improving the accuracy of diagnoses, improving treatments, and evolving medical care.

stockstobuy.jpg

These fresh technological developments continue to boost excitement within the market. Demand for healthcare is forecast to grow as the aging population increases and a rise in prevalence of chronic diseases.  From data-based approaches to potential blockbuster drug candidates, advancements in healthcare may catalyze opportunities for investors looking to healthcare stocks.

Premier Health Group, Inc. (PHGRF) (PHGI) announced it is growing its development team at Cloud Practice Inc. to support its focus on digitizing healthcare by hiring four new full-time employees, three Web Software Developers and one User Interface/User Experience Designer to support the build out of its patient centric platform and mobile app – a beta version of which will be available by end of Q2, according to the company. The new patient portal will provide Cloud Practice clients with additional services which will be provided via a SaaS (software-as-a-service) model, allowing for new recurring revenues that are scalable and will initially be extended to the 290 clinics in Premier Health’s ecosystem.

“The future of healthcare is digitally driven and this strategic investment in growing Cloud Practice’s team will enable us to fast-track the build out our app – a much-needed technology innovation in healthcare,” said Dr. Essam Hamza, CEO. “Our goal is to tackle the accessibility bottlenecks by putting the power in the hands of patients. Not only will our app enable patients’ access to their health care providers, but also allow for cohesive patient care by coordinating and connecting all members of their health care team.”

Premier Health recently announced expansion plans to formally enter the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers in order to partner with a, or multiple, Licensed Producers. The company is also in the process of closing on two operating pharmacies in Metro Vancouver, with a combined revenue of approximately $6 million (FY 2018) and anticipates the acquisition to close in or about Q2 2019 and entered into a strategic partnership with a major online healthcare company in China, 360 Health enabling the Premier’s healthcare team to connect with patients virtually in China to provide second opinion services.

Biocept Inc. (BIOC) announced that it will collaborate with Providence St. Joseph Health, Southern California, and its wholly owned affiliates Providence Saint John’s Health Center and the John Wayne Cancer Institute, to conduct a study to validate the use of cerebrospinal fluid (CSF) as a specimen type with Biocept’s Target Selector™ liquid biopsy platform.

Biocept’s liquid biopsy platform will be used to evaluate the CSF of patients diagnosed with certain types of cancer, such as breast, lung and melanoma, as well as other malignancies to determine if leptomeningeal metastases have occurred. The results from Biocept’s liquid biopsy testing will be compared to standard methods for confirming the diagnosis of leptomeningeal metastases.

“We are very pleased to collaborate with Dr. Kesari and Providence St. Joseph Health in this study designed to further validate the clinical utility of our Target Selector™ platform using the CSF of patients with cancer,” said Michael W. Nall, President and CEO. “Among the significant advantages of our liquid biopsy technology is its versatility, which enables its application in a variety of clinical situations and for use with multiple types of biofluids. Results of this study could open new market opportunities for Biocept.”

Midatech Pharma (MTP) confirmed that further to its announcement made on January 29, 2019, the strategic investment by China Medical Systems Holdings Limited group (CMS) and A&B license agreement is now formally active. The investment by CMS and A&B, comprised an £8m subscription in Midatech, for a total of 207,792,206 Ordinary Shares at a price of 3.85 pence per share.

CMS has rights to develop and commercialize the Midatech’s pipeline of products in Greater China and certain South East Asian.  Subject to certain milestones being achieved, Midatech will be entitled to receive regulatory and sales-based milestone payments as well as royalty payments. The collaboration provides the company with access to the Chinese market and substantial investment and funds for Midatech’s current key programs, as well as additional CMS funded opportunities for the Company’s technology platforms Q-Sphera, MidaSolve, and MidaCore.

Dr Craig Cook, CEO, said: “We are delighted to finalise the licence agreement with China Medical Systems, a leading Hong Kong based Chinese pharmaceutical company. This is a key collaboration for Midatech that provides a strong endorsement of our technologies and pipeline whilst establishing a solid foundation for a successful and ambitious long-term partnership. The agreement will enable development of current and new products and extend our reach to the important markets of China and South East Asia. We look forward to developing this collaboration with CMS.”

biotechstocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.

 

3 Healthcare Stocks Gaining Investor Attention

Healthcare stocks are gaining momentum again this week, as sector trends in technology and new treatments for diseases are generating increased interest among investors. According to Modern Healthcare, “the healthcare industry has long fueled the country’s economy. Demand is expected to pick up as the population ages, people live longer, more gain insurance coverage and chronic conditions become more prevalent”.

healthcarestocks.jpg

As healthcare companies work to develop new methods to improve the quality of care that can be provided, whether it be technology, devices or drugs, the industry, in its entirety, is expected to unite to meet the demands and needs of consumers seeking quality healthcare. With the growing global demand for healthcare, stocks within the sector are starting to see higher activity in the markets.

Premier Health Group, Inc. (PHGRF) (PHGI) recently provided a corporate update.  The company announced as a part of its expansion plans, it is formally entering the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers in order to partner with a, or multiple, Licensed Producers. Premier Health’s recent acquisition of Cloud Practice, a medical software company, has provided the company with an underlying platform to help empower and streamline patient-doctor interaction.

“We are currently working on a partnership model to hard code the decision-making process into the Electronic Medical Records (EMR),” said Dr. Essam Hamza, CEO. “There has been a critical gap between the patient’s need for medical cannabis and the doctor’s knowledge and comfort level in prescribing it. At Premier we understand the frustration felt from both the patient and the doctor and are integrating what we think is a revolutionary process. This new tool will allow us to provide a much-needed service to the 287 clinics and almost 3 million patients in our ecosystem.”

Premier Health is also in the process of closing on two operating pharmacies in Metro Vancouver, with a combined revenue of approximately $6 million (FY 2018) and anticipates the acquisition to close in or about Q2 2019. The company also recently announced a partnership with a major online healthcare company in China, 360 Health enabling the Premier’s healthcare team to connect with patients virtually in China to provide second opinion services.

ARCA biopharma, Inc. (ABIO) announced reaching an agreement with the U.S. FDA regarding a Special Protocol Assessment (SPA) on the design of Phase 3 clinical trial, PRECISION-AF, to assess the safety and efficacy of GencaroTM as a genetically-targeted treatment for atrial fibrillation (AF) in patients with a specific type of heart failure (HF) which currently has no FDA approved drug therapies.

“Consistent with our mission to develop precision therapies on a pharmacogenetic platform, this SPA agreement with the FDA provides a clearly defined regulatory pathway for the Phase 3 development of Gencaro in a genotype-specific heart failure population that currently has no FDA approved drug therapy,” said Michael R. Bristow, MD, PhD, CEO. “If the previous foundational therapeutic observations in the GENETIC-AF and BEST trials are confirmed in PRECISION-AF, we believe Gencaro could potentially provide a new standard of treatment for AF prevention for the estimated 2.5 million HFmrEF patients in the major markets in U.S., Europe and Japan.”

If the PRECISION-AF trial is successful and Gencaro gains regulatory approval, it has the potential to be the first genetically-targeted cardiovascular therapy, the only drug therapy indicated in HF patients with mid-range ejection fraction (HFmrEF) and the only drug therapy for AF approved against an active comparator.

Clearside Biomedical, Inc. (CLSD) announced that it received notification from the U.S. FDA that the Agency has accepted for review the New Drug Application (NDA) for XIPERE for Suprachoroidal Injection for the treatment of macular edema associated with uveitis. The FDA has determined that the application is sufficiently complete to permit a substantive review.

The NDA filing is supported by data from the Phase 3, PEACHTREE clinical trial that demonstrated significant and clinically meaningful improvement in vision for patients with macular edema associated with non-infectious uveitis, and that improvement was achieved across all anatomical locations of uveitis. Also, in patients with active inflammation at baseline, resolution was achieved in more than two-thirds of those treated with XIPERE across three commonly used measures of inflammation: vitreous haze, anterior chamber cells and anterior chamber flare.

“We are delighted with this positive news on our XIPERE NDA. If XIPERE is approved, Clearside will have the first therapy indicated for patients suffering from macular edema associated with uveitis,” said Daniel H. White, President and CEO. “Macular edema is the leading cause of vision loss, and even blindness, in uveitis patients, and we are now one step closer to treating this underserved patient population. Over the last several months, our team has worked diligently to reach this milestone and we are now preparing to launch the product if approved.”

biotechstocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.

3 Healthcare Stocks Setting The Pace On Wednesday

Over the next several years, large transformations are expected to disrupt the healthcare industry.  The market research firm, Frost & Sullivan, predicts that this year will be the year for technology such as big data analytics, artificial intelligence, and mHealth to drive the industry to more sustainable business models.

healthcarestocks.jpg

Sandeep Sinha of Frost & Sullivan stated, “Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally. Advances in areas ranging from cancer immunotherapy products to blood testing, as well as the convergence of cutting-edge technology such as artificial intelligence and blockchain will help shape the healthcare industry into a much-anticipated, value-based care paradigm”.

Healthcare companies working to develop novel approaches to traditional care offerings may catalyze opportunities to investors looking to healthcare stocks.

Premier Health Group, Inc. (PHGRF) (PHGI) annouced that it has acquired all of the outstanding securities of Cloud Practice Inc., a medical software company. The combined Premier and Cloud Practice ecosystem consists of over 3,000,000 patients and provides the company with an underlying platform to help empower and streamline patient-doctor interaction.

“We are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system,” said Dr. Essam Hamza, CEO.

Premier Health most recently announced it is formally entering the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers in order to partner with a, or multiple, Licensed Producers and expects to provide additional updates later this quarter. The company is also moving forward with a binding LOI to acquire two Vancouver-based pharmacies and anticipates the acquisition to close in or about Q2 2019. Premier has also entered into a strategic partnership with China’s 360 Health, whereby Premier will be provide second opinion services by connecting 360 Health’s patients in China with doctors in Canada both remotely and in person.

ReWalk Robotics, Ltd. (RWLK) develops, manufactures and markets wearable robotic exoskeletons for lower limb disabilities as a result of spinal cord injury or stroke. The company announced today that Cigna Corporation (CI)   has revised its previous non-coverage policy regarding coverage of exoskeleton medical devices and will now review submissions on a case-by-case basis to consider providing coverage based on medical criteria. This policy revision is the first of its kind by a major private insurer for individuals eligible to use exoskeleton devices.

“This is a major milestone for healthcare beneficiaries in the United States,” said CEO Larry Jasinski. “Cigna is leading by example with its understanding of emerging technologies, a focus on improving the overall health and well-being of beneficiaries, and most of all, in the development of progressive policies. This new policy is expected to have an immediate impact on the lives of qualified beneficiaries who will now have access to life changing medical devices.”

ReWalk recently reported Q4 financial results in which highlights include: Total revenue for the quarter was $1.6 million compared to $1.5 million in the prior year, sales in Europe grew to $1.24 million driven primarily by the German national coverage code that was issued in June 2018 and 2018 gross margin improved to 43.2%, from 40.0% in 2017.

Geron Corporation (GERN) coverage was initiated today by BTIG Research with a Buy rating and new price target of $4.  Geron recently announced several key leadership decisions over the past month as the company works to restructure their in-house development team to further support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019.

The company announced the appointment of a new chief medical officer Dr. Aleksandra Rizo. Israel Gutierrez, M.D. as Vice President, Pharmacovigilance and Drug Safety and Andrew J. Grethlein, Ph.D., as Executive Vice President and Chief Operating Officer.

“As we transition to a late-stage development company, we are very pleased to welcome Dr. Aleksandra Rizo to Geron as Chief Medical Officer,” said John A. Scarlett, M.D., Chairman and CEO. “With Aleksandra’s prior experience as the clinical lead for the imetelstat program for more than three years at Janssen, as well as her wealth of leadership experience with other hematology-oncology development projects at both Janssen and Celgene, we believe she is uniquely suited to build and lead our clinical development team.”

biotechstocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.

3 Healthcare Stocks To Watch This Week

Market research firm Frost & Sullivan will be hosting a Growth Innovation Leadership briefing titled “2019 Healthcare Predictions Unleashed – Growth Opportunities, Technology, and Trends later this year.” The firm has already stated that globally, 2019 will be a year of value-based care as it anticipates the outcomes-based care focus to globalize.

healthcarestocks.jpg

“Favorable reimbursement policies for clinically relevant digital health applications will expand care delivery models beyond physical medicine. 2019 will be a reality check for two of the most hyped healthcare technologies of this decade such as artificial intelligence (AI) and blockchain.”

Healthcare companies are working diligently to discover and create not only innovative but effective solutions to improve the quality of care to advance the industry. As the demand for novel healthcare solutions grows, companies that are looking to disrupt the industry and change traditional care offerings may create opportunity to investors looking to healthcare stocks.

Premier Health Group, Inc. (PHGRF) (PHGI) announced it has acquired all of the outstanding securities of Cloud Practice Inc., a medical software company. Cloud Practice will join the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers. The combined Premier and Cloud Practice ecosystem consists of over 3,000,000 patients.

“We are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system,” said Dr. Essam Hamza, CEO.

Premier Health is moving forward with a binding Letter of Intent to acquire two cash flow positive Metro Vancouver-based pharmacies with a combined annual revenue of over $6 million for the fiscal year and expects the acquisition to close in or about Q2 2019.  The company also recently entered into a strategic partnership with China’s 360 Health, a healthcare subsidiary of 360 Security Technology.  The two companies will implement an infrastructure whereby Premier will be providing second opinion services by connecting 360 Health’s patients in China with doctors in Canada both remotely and in person.

BioLineRx Ltd. (BLRX) announced that the U.S. FDA has granted Orphan Drug Designation to its lead oncology candidate. Orphan Drug Designation by the FDA warrants BioLineRx to 7 years of market exclusivity for the use of BL-8040 for the treatment of pancreatic cancer, if approved.  It also entitles the company to tax credits related to clinical trial expenses, an exemption from the FDA-user fee, and FDA assistance in clinical trial design.

“Orphan Drug Designation in pancreatic cancer is a very important milestone in the development plan of BL-8040, and joins previously approved orphan designations by the FDA for BL-8040 in AML and stem-cell mobilization,” stated Philip Serlin, CEO. “We have previously reported encouraging clinical data supporting the potential of BL-8040 as part of an immunotherapy combination treatment in pancreatic cancer, and we look forward to top-line results from our ongoing pancreatic clinical studies later this year.”

BL-8040, for the treatment of pancreatic cancer. Presently, BL-8040 is in two separate immuno-oncology collaboration clinical studies targeting pancreatic cancer with Merck & Co., Inc., (MRK) and a collaboration with Genentech, a member of the Roche Group (RHHBY).

Evolus, Inc. (EOLS) announced that the U.S FDA has approved its lead product, Jeuveau™, for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines, associated with corrugator and/or procerus muscle activity in adults.

David Moatazedi, President and CEO said, “We are focusing our efforts on ensuring a successful launch of Jeuveau™ and have initiated the recruitment of a high-quality, specialized U.S. sales force. The launch of Jeuveau™ will be powered by our technology platform designed to eliminate the friction points that exist for customers today. Prior to our U.S. launch, we expect publication of our U.S. Phase III results and to submit for publication our European and Canadian head-to-head Phase III study versus Botox®. I would like to thank all the Evolus employees, clinical investigators, patients and our partner Daewoong for their diligent efforts in bringing a new option to the market”.

Jeuveau™ is expected to be available throughout the United States at physician offices starting in Spring 2019.

pharmaceuticalstocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.